Oral Bisphosphonate Use and All‐Cause Mortality in Patients With Moderate–Severe (Grade 3B‐5D) Chronic Kidney Disease: A Population‐Based Cohort Study
暂无分享,去创建一个
C. Cooper | A. Díez-Pérez | C. Tebé | J. Center | Y. Ben-Shlomo | N. Arden | J. Pascual | F. Caskey | M. Javaid | A. Judge | M. Pérez-Sáez | B. Abrahamsen | D. Prieto-Alhambra | M. S. Ali | D. Bliuc | D. Alarkawi | N. Pallarés | L. Elhussein | N. Pallarès
[1] G. Block,et al. A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] P. Geusens,et al. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study , 2019, Osteoporosis International.
[3] P. Miller. Bone disease in CKD: a focus on osteoporosis diagnosis and management. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] M. Coco,et al. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] P. Miller,et al. Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option? , 2014, Osteoporosis International.
[6] P. Fine,et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). , 2003, Kidney international.
[7] E. Shane,et al. Relationship between moderate to severe kidney disease and hip fracture in the United States. , 2006, Journal of the American Society of Nephrology : JASN.
[8] Mei-Yi Wu,et al. Bone loss in chronic kidney disease: Quantity or quality? , 2016, Bone.
[9] H. Malluche,et al. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. , 2000, Journal of the American Society of Nephrology : JASN.
[10] O Johnell,et al. A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.
[11] Daniel Prieto-Alhambra,et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). , 2011, Informatics in primary care.
[12] M. Perazella,et al. Bisphosphonate nephrotoxicity. , 2008, Kidney international.
[13] I. Reid,et al. Effect of osteoporosis treatment on mortality: a meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.
[14] A. Garg,et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. , 2012, Kidney international.
[15] Chun-Yuh Yang,et al. The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study , 2013, BMC Nephrology.
[16] S. Majumdar,et al. Oral bisphosphonates are associated with reduced mortality after hip fracture , 2011, Osteoporosis International.
[17] NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. , 2001, Southern medical journal.
[18] S. Boonen,et al. Safety and Efficacy of Risedronate in Patients With Age‐Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] J. Eisman,et al. Osteoporosis medication and reduced mortality risk in elderly women and men. , 2011, The Journal of clinical endocrinology and metabolism.
[20] Cathleen S. Colón-Emeric,et al. Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men , 2010, Annals of Internal Medicine.
[21] R. Cumming,et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study , 2011, Osteoporosis International.
[22] ScienceDirect. American journal of kidney diseases : AJKD : the official journal of the National Kidney Foundation. , 1981 .
[23] S. Cummings,et al. Renal function and risk of hip and vertebral fractures in older women. , 2007, Archives of internal medicine.
[24] Frank G. Dickinson,et al. Highlights of the Conference , 1962 .
[25] Neil R. Powe,et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. , 2007, Kidney international.
[26] S. Cummings,et al. Effects of denosumab on fracture and bone mineral density by level of kidney function , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] B. Kestenbaum,et al. Increased risk of hip fracture among men with CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] D. Wheeler,et al. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) , 2017, Kidney international supplements.
[29] Craig S. Wong,et al. Increased risk of hip fracture among patients with end-stage renal disease. , 2000, Kidney international.
[30] S. Boonen,et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. , 2008, Kidney international.
[31] Daniel Prieto-Alhambra,et al. Linking of Primary Care Records to Census Data to Study the Association between Socioeconomic Status and Cancer Incidence in Southern Europe: A Nation-Wide Ecological Study , 2014, PloS one.
[32] J. Eisman,et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.
[33] Supplemental Tables,et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.
[34] K. Bhaskaran,et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.
[35] L. Smeeth,et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review , 2010, British journal of clinical pharmacology.
[36] M. Baumann,et al. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid , 2008, Internal medicine journal.
[37] Seth M. Arum,et al. Management of adynamic bone disease in chronic kidney disease: A brief review , 2016, Journal of clinical & translational endocrinology.
[38] M. Nevitt,et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. , 2000, Archives of internal medicine.
[39] K. Burns,et al. Severe hypocalcemia following denosumab injection in a hemodialysis patient. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[40] P. Eiken,et al. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study , 2012, Osteoporosis International.
[41] J. B. Layton,et al. Propensity Score Methods for Confounding Control in Nonexperimental Research , 2013, Circulation. Cardiovascular quality and outcomes.
[42] J. Avorn,et al. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. , 2010, American journal of epidemiology.
[43] A. Collins,et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. , 2005, Journal of the American Society of Nephrology : JASN.
[44] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[45] P. Miller. Chronic kidney disease and osteoporosis: evaluation and management. , 2014, BoneKEy reports.
[46] J. Eisman,et al. Risk of subsequent fracture after low-trauma fracture in men and women. , 2007, JAMA.
[47] S. Cummings,et al. Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[48] R J Glynn,et al. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs , 2014, Journal of internal medicine.